Cytori Therapeutics, Inc.
PSTV US72941H5090
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Lenk Robert P |
0.49 USD |
110,000 Bought |
53,779 USD |
22/08/2025 | 22/08/2025 |
| Hawkins Richard J |
1.50 USD |
4,000 Bought |
5,996 USD |
13/09/2024 | 13/09/2024 |
| Hawkins Richard J |
1.35 USD |
6,285 Bought |
8,512 USD |
12/09/2024 | 12/09/2024 |
| Petersen Greg |
1.35 USD |
12,500 Bought |
16,875 USD |
11/09/2024 | 11/09/2024 |
| Clowes Howard |
1.34 USD |
5,000 Bought |
6,681 USD |
11/09/2024 | 11/09/2024 |
| Sims Andrew John Hugh Macintyre CFO |
1.27 USD |
4,098 Bought |
5,204 USD |
10/09/2024 | 10/09/2024 |
| Hedrick Marc H CEO |
1.23 USD |
8,000 Bought |
9,839 USD |
10/09/2024 | 10/09/2024 |
| Hawkins Richard J |
2.04 USD |
4,902 Bought |
10,000 USD |
08/05/2024 | 08/05/2024 |
| Lenk Robert P |
2.04 USD |
4,167 Bought |
8,501 USD |
08/05/2024 | 08/05/2024 |
| Petersen Greg |
2.04 USD |
12,255 Bought |
25,000 USD |
08/05/2024 | 08/05/2024 |